Indication:Rheumatoid arthritis in combination with methotrexate, in adults with an inadequate response to methotrexate alone.
Anakinra is not recommended for the treatment of RA, except in the context of a controlled, long-term clinical study.
Patients currently receiving anakinra for RA may suffer loss of wellbeing if their treatment were discontinued at a time they did not anticipate. Therefore, patients should continue therapy with anakinra until they and their consultant consider it is appropriate to stop.
Do not offer the combination of tumour necrosis factor-a (TNF-a) inhibitor therapy and anakinra for RA.